Joseph Nguyen, MD
Family Medicine · Oklahoma City, OKNPI 1063723195
Payments from drug & device makers
Across 540 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Pfizer$955
- GSK$790
- Astellas Pharma US Inc$588
- Novo Nordisk$542
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,443100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $1,176 |
| Lilly USA, LLC | 76 | $1,089 |
| Pfizer | 74 | $955 |
| GSK | 59 | $790 |
| Astellas Pharma US Inc | 27 | $588 |
| Novo Nordisk | 42 | $542 |
| AbbVie | 23 | $487 |
| Boehringer Ingelheim | 24 | $411 |
| Amgen(2 entities) | 23 | $346 |
| Merck | 27 | $324 |
| Bayer | 18 | $279 |
| Sumitomo Pharma America, Inc. | 13 | $262 |
| Exact Sciences | 8 | $144 |
| Abbott | 8 | $127 |
| Sanofi-aventis U.S. LLC | 8 | $126 |
| Idorsia Pharmaceuticals US Inc | 6 | $97 |
| Dexcom, Inc. | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $92 |
| Amarin Pharma, Inc. | 5 | $86 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| Mylan Specialty L.p. | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Viatris Specialty LLC | 1 | $30 |
| Redhill Biopharma Inc. | 2 | $25 |
| Alkermes, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Edwards Lifesciences | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Novartis | 1 | $13 |
| Biogen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,449 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $133,309 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $51,131 |
| JardianceEmpagliflozin | 34 | $45,984 |
| EliquisApixaban | 39 | $45,825 |
| JanuviaSitagliptin Phosphate | 30 | $44,030 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $21,235 |
| XareltoRivaroxaban | 20 | $18,948 |
| TrulicityDulaglutide | 11 | $18,860 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $13,333 |
| Atorvastatin Calcium | 473 | $6,219 |
| Tamsulosin Hcl | 195 | $4,253 |
| Rosuvastatin Calcium | 152 | $3,669 |
| Losartan Potassium | 218 | $2,981 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 124 | $2,923 |
| Levothyroxine Sodium | 217 | $2,410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $542 | $133,309107 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $790 | $64,46379 claims |
| PfizerEliquis, Paxlovid | $955 | $47,23352 claims |
| Boehringer IngelheimJardiance | $411 | $45,98434 claims |
| MerckJanuvia | $324 | $44,03030 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $126 | $21,23524 claims |
| Johnson & JohnsonXarelto | $16 | $18,94820 claims |
| Lilly USA, LLCTrulicity | $1,089 | $18,86011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.